Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Last trade$1.73
Day change+$0.01 (+0.58%)
Day range$1.71 – $1.77
Volume14,865
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.81M
Price / earnings
—
Price / book
0.03×
Price / sales
—
EV / sales
—
EV / EBITDA
11.34×
Profitability
Earnings per share
-$69.03
Return on assets
-106.12%
Return on equity
-107.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
97.7×
Quick ratio
97.7×
Cash ratio
96.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PCSA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.29M
$1.69M
$1.52M
$1.59M
$1.83M
$1.5M
$1.26M
$1.02M
Research and development
$1.81M
$649.88K
$1.81M
$2.11M
$1.66M
$2.45M
$1.59M
$1.71M
Total operating expenses
$184.13M
$2.34M
$3.33M
$3.7M
$3.49M
$3.95M
$2.85M
$2.73M
Operating income
-$184.13M
-$2.34M
-$3.33M
-$3.7M
-$3.49M
-$3.95M
-$2.85M
-$2.73M
Interest expense
$1.01M
-$2K
$0
$0
$46K
$8.86K
$0
$0
Income before taxes
-$183.16M
-$3.27M
-$3.38M
-$3.36M
-$3.44M
-$3.93M
-$2.83M
-$2.73M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$183.16M
-$3.27M
-$3.38M
-$3.36M
-$3.44M
-$3.93M
-$2.83M
-$2.73M
Net income attributable to common shareholders
-$183.16M
-$3.27M
-$3.38M
-$3.36M
-$3.44M
-$3.93M
-$2.83M
-$2.73M
EBITDA
-$6.1M
-$2.34M
-$3.33M
-$3.7M
-$3.49M
-$3.95M
-$2.85M
-$2.73M
Basic earnings per share
-$61.58
-$1.19
-$1.29
-$1.44
-$1.81
-$6.26
-$7.58
-$19.39
Diluted earnings per share
-$61.58
-$1.19
-$1.29
-$1.44
-$1.81
-$6.26
-$7.58
-$19.39
Recent news
Company coverage with links to the original publishers.
Processa Pharmaceuticals announced key leadership appointments including Gregory J. Flesher as Chief Operating Officer, Craig Coburn as EVP Head of Research, Ashley Hall as EVP Development, and Michael P. Cruse as EVP Business Operations. These appointments follow the company's July 2026 acquisition of Vidya Therapeutics and $200 million financing. The company is advancing VT-7208, a next-generation BTK inhibitor, across Phase 2 studies in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, with FDA clearance recently received for the CSU study.
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, highlighting its pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri).
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced its participation in the 2025 BIO CEO & Investor Conference, where it will present a corporate overview and hold one-on-one meetings with investors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.